Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Immunomedics wins new US patents
The allowed claims cover the use of veltuzumab and bispecific antibody protein constructs for the treatment and diagnosis of B-cell disorders, such as B-cell malignancies and autoimmune diseases.
The allowed claims cover the use of veltuzumab and bispecific antibody protein constructs for the treatment and diagnosis of B-cell disorders, such as B-cell malignancies and autoimmune diseases.
Mirixa Australia, a newly formed business venture, will be operated by the Guild’s healthlinks.net subsidiary. Under the agreement, Mirixa, which is sponsored by the National Community Pharmacists Association,
Tianyin has previously received the official approval from the Chinese State Food and Drug Administration (SFDA) to produce Azithromycin dispersible tablets in two dosage forms, 0.25gm and 0.1gm.
Mr Leng has been working for General Atlantic since 2007 and is based in China. Prior to joining General Atlantic, Mr Leng served as a managing director at
Part one was a randomized two-way crossover comparison study in 12 healthy subjects to test the pharmacokinetics, safety and tolerability of the original active pharmaceutical ingredient in capsule
Since January 2008, D’Agostino has been serving as Milestone’s acting CFO. Before joining Milestone, D’Agostino served as senior vice president and treasurer of Summit Global Logistics, a publicly
Elesclomol is a novel, oxidative stress inducing, small molecule drug candidate currently undergoing Phase III clinical investigation in metastatic melanoma, the Symmetry trial, with other trials in other
The study validates the company’s CellOptics platform and proprietary digital microscope, the Ikoniscope, as a viable method for quickly and easily detecting and detailing circulating tumor cells (CTC)
The transition to Integra Spine will align the spinal implant business more closely with the Integra corporate brand. Integra LifeSciences has previously acquired the Theken companies, which includes
Par has earlier announced a resizing of its generic business as part of an ongoing strategic assessment of the overall business. Mr Martino will stay on through the